Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer

Cancer Science

Volumn 95, Issue 8, 2004, Pages 691-695

  Sekine, Ikuo ^a   Noda, Kazumasa ^c   Oshita, Fumihiro ^c   Yamada, Kouzou ^c   Tanaka, Manabu ^c   Yamashita, Kosuke ^c   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Kunitoh, Hideo ^a   Ohe, Yuichiro ^a   Tamura, Tomohide ^a   Kodama, Tetsuro ^a   Sumi, Minako ^b   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b National Cancer Hospital   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOMYCIN; NAVELBINE; SEROTONIN 3 ANTAGONIST; STEROID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL MENINGITIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG RESPONSE; ESOPHAGITIS; FEMALE; HUMAN; HYPONATREMIA; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 4544239425     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03331.x     Document Type: Article

References (23)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-7.
2. Jett JR, Scott WJ, Rivera MP, Sause WT and American College of Chest Physicians. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003; 123: 221S-5S.
3. Pierre F, Maurice P, Gilles R, Pascal T, Pierre-Jean S, Hervé L, Alain V, Jean-Yves D, Francoise M, Fancoise M. A randomized phase III trial of sequential chemoradiotherapy in locally advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2001; 20: 312a (abstr 1246).
4. Curren W Jr, Scott C, Langer C, Komaki R, Lee J, Hauser S, Movsas B, Wasserman TH, Rosenthal S, Byhardt R, Sause W, Cox J. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresectable stage III non-small-cell lung cancer (NSCLC): initial report of the Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000; 19: 484a (abstr 1891).
5. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-9.
6. Kubota K, Tamura T, Fukuoka M, Furuse K, Ikegami H, Ariyoshi Y, Kurita Y, Saijo N. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. Ann Oncol 2000; 11: 445-50.
7. Furuse K, Kubota K, Kawahara M, Kodama N, Ogawara M, Akira M, Nakajima S, Takada M, Kusunoki Y, Negoro S, Matsui K, Masuda N, Takifuji N, Kudoh S, Nishioka M, Fukuoka M. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group. J Clin Oncol 1995; 3: 869-75.
8. Atagi S, Kawahara M, Hosoe S, Ogawara M, Kawaguchi T, Okishio K, Naka N, Sunami T, Mitsuoka S, Akira M. A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. Lung Cancer 2002; 36: 105-11.
9. Sekine I, Saijo N. Novel combination chemotherapy in the treatment of non-small cell lung cancer. Exp Opin Pharmacother 2000; 1: 1131-61.
10. Furuse K, Fukuoka M, Kuba M, Yamori S, Nakai Y, Negoro S, Katagami N, Takada Y, Kinumaki E, Kawahara M, Kubota K, Sakuma A, Niitani H. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group. Ann Oncol 1996; 7: 815-20.
11. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
12. Perol M, Guerin JC, Thomas P, Poirier R, Carles P, Robinet G, Kleisbauer JP, Paillotin D, Vergnenegre A, Balmes P, Touron D, Grivaux M, Pham E. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Francais de Pneumo-Cancerologie.' Lung Cancer 1996; 14: 119-34.
13. Kawahara M, Furuse K, Nishiwaki Y, Horai T, Saijo N, Hasegawa K, Ohashi Y, Niitani H. Randomized study of vinorelbine (VRB) or vindesine (VDS) with cisplatin (C) and mitomycin (M) as induction chemotherapy in stage IIIB or IV non-small cell lung cancer (NSCLC)-final results. Proc Am Soc Clin Oncol 2000; 19: 489a (abstr 1914).
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbonne PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
15. JCOG Administrational Committee: National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 2.0, Jan 30, 1998). Japanese edition by JCOG. Available at http://www.med.gunma-u.ac.jp/event/CTCJ_v20.pdf
16. WHO. Handbook for reporting results of cancer treatment. WHO Offset Publication no. 48. Geneva: World Health Organization; 1979.
17. Armitage P, Berry G. Survival analysis. In: Statistical methods in medical research. 3rd ed. Oxford: Blackwell Sci Publ; 1994. p. 469-92.
18. Sekine I, Matsuda T, Saisho T, Watanabe H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N. Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity. Jpn J Clin Oncol 2000; 30: 401-5.
19. Masters GA, Haraf DJ, Hoffman PC, Drinkard LC, Krauss SA, Ferguson MK, Olak J, Samuels BL, Golomb HM, Vokes EE. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 1998; 16: 2157-63.
20. Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Mikker AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002; 20: 4191-8.
21. Zatloukal P, Petruzelka L, Zemanova M, Krejbich F, Havel L. Vinorelbine (VRL) plus cisplatin (CDDP) and concurrent radiotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 505a (abstr 1947).
22. Alcedo J, Gallardo D, Lopez-Mariscal A, Calderillo G, Green L, Correa E, Zamora J, Mohar A. Cisplatin/vinorelbine (CDDP/VNR) and radiotherapy (XRT) in advanced non-small cell lung cancer (ANSCLC): an effective and feasible option with no need for dose reduction. Proc Am Soc Clin Oncol 1999; 18: 494a (abstr 1905).
23. Hotta K, Sekine I, Tamura T, Sawada M, Watanabe H, Kusaba H, Akiyama Y, Inoue A, Shimoyama T, Nokihara H, Ueda Y, Yamamoto N, Kunitoh H, Ohe Y, Kodama T, Saijo N. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2001; 31: 596-600.